Lymphotoxin beta: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 29: | Line 29: | ||
[[Category:Cell biology]] | [[Category:Cell biology]] | ||
{{Medicine-stub}} | {{Medicine-stub}} | ||
{{No image}} | |||
__NOINDEX__ | |||
Latest revision as of 18:01, 17 March 2025
Lymphotoxin beta (LTβ) is a type of cytokine, a broad category of small proteins that are important in cell signaling. It is a member of the tumor necrosis factor (TNF) family, a group of cytokines that stimulate the acute phase reaction.
Function[edit]
LTβ is produced by lymphocytes, a type of white blood cell involved in the immune response. It is a potent inducer of the inflammatory response and can cause cell death. LTβ plays a crucial role in the development of secondary lymphoid tissues such as lymph nodes and Peyer's patches.
Structure[edit]
The LTβ protein is a homotrimer, meaning it is composed of three identical subunits. Each subunit is a polypeptide chain that folds into a specific three-dimensional structure. The three subunits are held together by disulfide bonds, a type of covalent bond that is particularly strong.
Clinical significance[edit]
Abnormal production or function of LTβ has been implicated in a variety of diseases, including autoimmune diseases, inflammatory bowel disease, and certain types of cancer. For example, overproduction of LTβ has been observed in patients with rheumatoid arthritis, a chronic inflammatory disorder.
Research[edit]
Research into the role of LTβ in disease is ongoing. Understanding how this cytokine functions could lead to new treatments for a variety of conditions. For example, drugs that inhibit the action of LTβ could potentially be used to treat inflammatory diseases.
See also[edit]
